Ironwood Pharmaceuticals (NASDAQ:IRWD) Upgraded at StockNews.com

Ironwood Pharmaceuticals (NASDAQ:IRWD) was upgraded by StockNews.com from a “buy” rating to a “strong-buy” rating in a research note issued to investors on Monday.

A number of other research firms have also weighed in on IRWD. Craig Hallum cut their price objective on shares of Ironwood Pharmaceuticals from $14.00 to $10.00 and set a “buy” rating for the company in a research report on Friday, August 9th. Leerink Partnrs raised shares of Ironwood Pharmaceuticals to a “hold” rating in a research report on Monday, September 9th. Wells Fargo & Company lowered their target price on shares of Ironwood Pharmaceuticals from $14.00 to $12.00 and set an “overweight” rating for the company in a report on Friday, August 9th. Leerink Partners assumed coverage on shares of Ironwood Pharmaceuticals in a report on Monday, September 9th. They issued a “market perform” rating and a $5.00 target price for the company. Finally, Capital One Financial downgraded shares of Ironwood Pharmaceuticals from an “overweight” rating to an “equal weight” rating and lowered their target price for the company from $12.00 to $4.00 in a report on Thursday, August 8th. Three investment analysts have rated the stock with a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, Ironwood Pharmaceuticals presently has an average rating of “Moderate Buy” and an average price target of $12.17.

Ironwood Pharmaceuticals Price Performance

IRWD remained flat at $4.19 during midday trading on Monday. 1,146,623 shares of the company’s stock were exchanged, compared to its average volume of 2,965,169. The firm has a market cap of $669.31 million, a PE ratio of 104.75 and a beta of 0.47. The company’s fifty day moving average price is $4.34 and its 200-day moving average price is $5.67. Ironwood Pharmaceuticals has a one year low of $3.79 and a one year high of $15.70.

Insiders Place Their Bets

In other news, insider Minardo John sold 9,910 shares of the company’s stock in a transaction on Monday, August 12th. The shares were sold at an average price of $4.27, for a total value of $42,315.70. Following the completion of the transaction, the insider now directly owns 284,661 shares in the company, valued at approximately $1,215,502.47. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 12.90% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in IRWD. Russell Investments Group Ltd. raised its holdings in Ironwood Pharmaceuticals by 244.8% in the first quarter. Russell Investments Group Ltd. now owns 777,847 shares of the biotechnology company’s stock valued at $6,775,000 after acquiring an additional 552,227 shares in the last quarter. Entropy Technologies LP acquired a new stake in Ironwood Pharmaceuticals in the first quarter valued at $693,000. First Eagle Investment Management LLC raised its holdings in Ironwood Pharmaceuticals by 10.5% in the first quarter. First Eagle Investment Management LLC now owns 1,002,225 shares of the biotechnology company’s stock valued at $8,729,000 after acquiring an additional 95,000 shares in the last quarter. State Board of Administration of Florida Retirement System raised its holdings in Ironwood Pharmaceuticals by 339.4% in the first quarter. State Board of Administration of Florida Retirement System now owns 195,057 shares of the biotechnology company’s stock valued at $1,699,000 after acquiring an additional 150,663 shares in the last quarter. Finally, GSA Capital Partners LLP acquired a new stake in Ironwood Pharmaceuticals in the first quarter valued at $1,534,000.

Ironwood Pharmaceuticals Company Profile

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.